Univariate and multivariate analyses of pretransplant and posttransplant factors and outcome for patients who underwent autologous transplantation in first remission (AUTO1), autologous transplantation beyond first remission (AUTO2), or nonmyeloablative allogeneic stem cell transplantation (NST)
| Group . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| Median (mo) . | P . | Hazard ratio . | P . | |
| Progression-free survival | ||||
| AUTO1 | ||||
| Marrow graft | 18 (vs 67) | < .001 | 8.3 | < .001 |
| B symptoms | 18 (vs 44) | .02 | 3.1 | .006 |
| AUTO2 | No factor identified | |||
| NST | ||||
| Peripheral blood graft and best chimerism ≥ 95% | NR (vs 20) | .02 | 0.25 | .008 |
| Acute GVHD | 22 (vs NR) | .03 | ||
| ≥ 5 prior therapies | 15 (vs NR) | .04 | 4.0 | .02 |
| Overall survival | ||||
| AUTO1 | ||||
| Marrow graft | 24 (vs 98) | < .001 | 7.2 | < .001 |
| B symptoms | 41 (vs 107) | .02 | 4.6 | .002 |
| HSCT-CI ≥ 3 | 70 (vs 131) | .05 | ||
| AUTO2 | No independent factor identified | |||
| B symptoms | 32 (vs 61) | .04 | ||
| β2m ≥ 3 mg/L | 22 (vs 72) | .05 | ||
| Total body irradiation | 42 (vs 104) | .04 | ||
| HSCT-CI ≥ 3 | 48 (vs 72) | .04 | ||
| NST | ||||
| Acute GVHD | 23 (vs NR) | .009 | 3.9 | .02 |
| ≥ 5 prior therapies | 23 (vs NR) | .03 | ||
| Chronic GVHD | 42 (vs NR) | .03 | ||
| Group . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| Median (mo) . | P . | Hazard ratio . | P . | |
| Progression-free survival | ||||
| AUTO1 | ||||
| Marrow graft | 18 (vs 67) | < .001 | 8.3 | < .001 |
| B symptoms | 18 (vs 44) | .02 | 3.1 | .006 |
| AUTO2 | No factor identified | |||
| NST | ||||
| Peripheral blood graft and best chimerism ≥ 95% | NR (vs 20) | .02 | 0.25 | .008 |
| Acute GVHD | 22 (vs NR) | .03 | ||
| ≥ 5 prior therapies | 15 (vs NR) | .04 | 4.0 | .02 |
| Overall survival | ||||
| AUTO1 | ||||
| Marrow graft | 24 (vs 98) | < .001 | 7.2 | < .001 |
| B symptoms | 41 (vs 107) | .02 | 4.6 | .002 |
| HSCT-CI ≥ 3 | 70 (vs 131) | .05 | ||
| AUTO2 | No independent factor identified | |||
| B symptoms | 32 (vs 61) | .04 | ||
| β2m ≥ 3 mg/L | 22 (vs 72) | .05 | ||
| Total body irradiation | 42 (vs 104) | .04 | ||
| HSCT-CI ≥ 3 | 48 (vs 72) | .04 | ||
| NST | ||||
| Acute GVHD | 23 (vs NR) | .009 | 3.9 | .02 |
| ≥ 5 prior therapies | 23 (vs NR) | .03 | ||
| Chronic GVHD | 42 (vs NR) | .03 | ||
Factors examined included: (1) age, sex, time from diagnosis, advanced stage (3/4) B symptoms, gastrointestinal involvement, blood involvement, blastic morphology, β2-microglobulin, lactate dehydrogenase; (2) International Prognostic Index (IPI), Mantle Cell IPI (MIPI), number of prior treatments, performance status, rituximab versus no rituximab, hyper-CVAD versus other regimens, disease status at transplantation, PET/Gallium scan at transplantation, conditioning regimen, stem cell source (PB vs BM); and (3) HSCT-CI. The following factors were applicable to nonmyeloablative stem cell transplantation patients only: sibling versus nonsibling donor, CMV status, sex mismatch, donor age, donor chimerism, acute GVHD, chronic GVHD, alemtuzumab exposure, and prior autologous transplantation.
NR indicates not reached; GVHD, graft-versus-host disease; PB, peripheral blood; BM, bone marrow; and HSCT-CI, Hematopoietic Stem Cell Transplantation-Comorbidity Index.